logo

Japan Drug Delivery Devices Market Size (2024 - 2029)

The Japan Drug Delivery Devices Market is anticipated to experience growth driven by the increasing prevalence of chronic diseases and advancements in technology. The market's expansion is supported by the rising adoption of drug delivery devices, which facilitate faster recovery for patients. The growing number of cancer, respiratory, and diabetic patients in Japan further contributes to the market's development, as these conditions necessitate effective drug delivery solutions.

Home Market Analysis Healthcare Research Device Drug Combination Research Drug Filled Devices Research Japan Drug Delivery Device Market Market Size

Market Size of Japan Drug Delivery Devices Industry

Market Snapshot1
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
Historical Data Period 2019 - 2022
CAGR 4.50 %

Major Players

rd-img

*Disclaimer: Major Players sorted in no particular order

Japan Drug Delivery Devices Market Analysis

The Japan Drug Delivery Devices Market is expected to register a CAGR of nearly 4.5% during the forecast period. The major factors driving the Japan Drug Delivery Devices Market are the rising prevalence of chronic diseases and technological advancements.

Drug delivery devices help in delivering the drugs which are beneficial for the targeted population to recover faster. In addition, a rising number of cancers, respiratory are diabetic patients in Japan will promote the adoption of drug delivery devices and drive the overall market. For instance, according to the estimates of the National Cancer Center - Center for Cancer Control and Information Services, the cancer incidence in 2018 was 1,013,600 in Japan, while the most common types of cancer were colorectum, stomach, lung, breast, and prostate cancer. Thus, owing to the above-mentioned factors is expected to drive market growth over the forecast period.

Japan Drug Delivery Devices Industry Segmentation

As per the scope, drug delivery devices or system are the tools which are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The Japan Drug Delivery Devices Market is segmented by route of administration, application and end user.

By Route of Administration
Injectable
Topical
Ocular
Other Route of Administration
By Application
Cancer
Cardiovascular
Diabetes
Infectious diseases
Other Applications
By End User
Hospitals
Ambulatory Surgical Centers
Other End Users
Need A Different Region Or Segment?
Customize Now

Japan Drug Delivery Devices Market Size Summary

The Japan Drug Delivery Devices Market is poised for steady growth, driven by the increasing prevalence of chronic diseases and advancements in technology. These devices play a crucial role in administering medications effectively, which is essential for the recovery of the targeted population. The rising incidence of conditions such as cancer, respiratory diseases, and diabetes in Japan is expected to enhance the adoption of these devices, thereby propelling market expansion. The National Cancer Center's data highlights a significant number of cancer cases, with common types including colorectal, stomach, lung, breast, and prostate cancers. This scenario underscores the importance of drug delivery devices in managing these health challenges, contributing to the market's positive outlook over the forecast period.

The market landscape in Japan is characterized by a competitive and fragmented environment, with several key players such as Mylan N.V., ANTARES PHARMA, INC., Tasei Kako Co. Ltd., GlaxoSmithKline Plc, Novartis AG, Bayer AG, Becton, Dickinson and Company, Johnson & Johnson, and 3M Company leading the charge. The increasing cancer mortality rate has prompted government and organizational initiatives to raise awareness about cancer and its treatments, further stimulating market growth. Additionally, the presence of robust research and development infrastructure in Japan is expected to support the ongoing expansion of the drug delivery devices market, positioning it for continued development in the coming years.

Explore More

Japan Drug Delivery Devices Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Chronic Diseases

      2. 1.2.2 Technological Advancements

    3. 1.3 Market Restraints

      1. 1.3.1 Risk of Needlestick Injuries

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Route of Administration

      1. 2.1.1 Injectable

      2. 2.1.2 Topical

      3. 2.1.3 Ocular

      4. 2.1.4 Other Route of Administration

    2. 2.2 By Application

      1. 2.2.1 Cancer

      2. 2.2.2 Cardiovascular

      3. 2.2.3 Diabetes

      4. 2.2.4 Infectious diseases

      5. 2.2.5 Other Applications

    3. 2.3 By End User

      1. 2.3.1 Hospitals

      2. 2.3.2 Ambulatory Surgical Centers

      3. 2.3.3 Other End Users

Japan Drug Delivery Devices Market Size FAQs

The Japan Drug Delivery Devices Market is projected to register a CAGR of 4.5% during the forecast period (2024-2029)

Mylan N.V., ANTARES PHARMA, INC., Tasei Kako Co. Ltd., GlaxoSmithKline Plc and Novartis AG are the major companies operating in the Japan Drug Delivery Devices Market.

Japan Connected Drug Delivery Devices Market Report Snapshots

Japan Drug Delivery Devices Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)